Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04881838Phase 3Active Not Recruiting

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

Role: collaborator

NCT05871099Phase 3Recruiting

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Role: collaborator

NCT05955391Phase 2Active Not Recruiting

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Role: collaborator

All 3 trials loaded